ALLR Allarity Therapeutics, Inc.
$0.92▲ +0.54%
Healthcare
Other
Volume 136.1K
Avg Volume (10D) 135.1K
Key Metrics & Fundamentals
Market Cap
$14.64M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.77 - 1.84
% vs 50 MA
-18.31%
% vs 200 MA
-24.73%
RSI-14
43.2
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.45
Free Cash Flow
-$2.56M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.42M
COGS
–
Operating Exp
$2.67M
Operating Income
-$2.67M
EBIT
-$2.67M
Pretax Income
-$3.41M
Net Income
-$3.41M
EPS (Diluted)
-0.21
Price & Volume History
Loading chart…
Recent News
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
Zacks · Oct 9, 2026 8:55 AM ET
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
ACCESS Newswire · Oct 5, 2026 8:30 AM ET
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
GlobeNewswire · Sep 30, 2026 9:00 AM ET
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
GlobeNewswire · Sep 28, 2026 8:00 AM ET
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
GlobeNewswire · Sep 15, 2026 8:00 AM ET
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
GlobeNewswire · Sep 11, 2026 8:00 AM ET
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
GlobeNewswire · Aug 14, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See ALLR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.